Clinical Trial Search

Primary: Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab — 83.1; 134.6 micrograms per milliliter (mcg/mL)

Primary: Child's Head Circumference Measurement (Measured at Birth) — 33.0; 33.8 cm

Primary: Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants — 6.95; 6.73; 5.21; 3.02 Episode per person year at risk — p=0.57

Primary: Overall Survival — 10.0; 10.2 months — p=0.4172

Primary: Prevention of Entry Dyspareunia With Non-hormonal Therapy — 5.3; 1.04; NA; 0.57 Units on a scale — p=0.0149

Primary: Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at…

Primary: Number of Patients With Investigator Defined Drug-related Adverse Events — 43; 43; 44 participants

Primary: Sustained Virological Response (SVR): Plasma HCV RNA Level < 25 IU/mL — 95.3; 54.7 percentage of participants

Primary: Overall Survival: Time From Randomization to Death From Any Cause — 9.8; 11.2 months — p=0.0062

Primary: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment…

Primary: Progression-free Survival — 1.8; 0.9 Months

Primary: Change From Baseline in Multidimensional Fatigue Inventory (MFI)--General Fatigue Subscale Score — -3.3; -1.8 units on a scale — p=0.23

Primary: Number of Participants Who Reported a 50% or Greater Reduction in Pain at 15 Minutes as Measured on the 100mm Visual Analog Scale — 48.8; 41.3 percentage of participants

Primary: Ability to Maintain Hemoglobin Level — 82.7; 82.6 percentage of participants

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks — -1.73; -1.33; -1.16 percentage of HbA1c